Form 4: Serina Therapeutics CSO Sells Shares Under 10b5-1 Plan

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, executed a pre-planned sale of 5,551 common shares after exercising stock options.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc., engaged in a transaction on October 28, 2025.
• The transaction involved the exercise of 5,551 stock options at an exercise price of $0.06 per share.
• Immediately following the exercise, 5,551 shares of common stock were sold at a weighted average price of $4.9615 per share.
• The sales occurred in multiple transactions ranging from $4.95 to $4.9625 per share.
• This transaction was conducted pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, Randall Moreadith beneficially owns 0 shares of common stock and 404,186 stock options.
• The stock options exercised were fully vested.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider transaction (exercise and sale of stock options) which is neutral in terms of company performance or outlook. It reflects a personal financial decision by an executive rather than a statement on the company's prospects.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on immediate, non-public information.
• The Chief Scientific Officer realized a significant profit from exercising options at $0.06 and selling shares at approximately $4.96.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, though this is a routine event for executives.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, such as the exercise of stock options and subsequent sale of shares, are common and routine events for executives in publicly traded companies across all industries. The use of a Rule 10b5-1 plan is a standard practice to manage insider trading compliance.

Comparison to Industry Standards

• This transaction is a standard insider stock option exercise and sale, consistent with practices observed across the biotechnology and pharmaceutical industries.
• Many executives utilize Rule 10b5-1 plans to manage personal liquidity and diversify holdings in a compliant manner.
• There are no specific comparable companies or projects mentioned in this filing to assess against industry benchmarks.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of ownership if new shares were issued upon exercise, but the impact is generally negligible for a transaction of this size. The pre-planned nature under Rule 10b5-1 mitigates concerns about opportunistic selling.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• This Form 4 filing does not mention any specific future actions, events, or milestones for the company.

Key Dates

Keywords

Serina Therapeutics, SER, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Randall Moreadith, Chief Scientific Officer, 10b5-1 Plan